Hepatosafe Antibiotics for Tuberculosis Treatment

Primary Hepatosafe TB Medications

The American Thoracic Society recommends streptomycin and ethambutol as the safest first-line options for treating tuberculosis in patients with liver disease or hepatotoxicity, as they have no hepatotoxic effects and can be used without dose adjustment or additional liver monitoring 1, 2
Streptomycin requires no precautions in hepatic disease and has no documented hepatotoxic effects, and is eliminated primarily by kidneys rather than metabolized by the liver 3
Ethambutol can be safely used in patients with liver disease without dose adjustment for hepatic impairment, with primary concern being ocular toxicity 1, 2

When hepatotoxicity develops, immediately stop rifampicin, isoniazid, and pyrazinamide, and continue treatment with streptomycin and ethambutol until liver function normalizes 1, 2
For infectious TB or clinically unwell patients, continue treatment with streptomycin and ethambutol until liver function normalizes, as this combination is safe and effective as a bridge regimen 1, 2, 4

The Centers for Disease Control and Prevention recommends avoiding the use of rifampin + pyrazinamide combination due to unacceptably high severe liver toxicity rate 6

Baseline liver function tests are required for hepatotoxic drugs, and drugs should be stopped if AST/ALT >5x normal or any elevation with symptoms or elevated bilirubin 1, 2
Weekly monitoring for 2 weeks, then biweekly for patients with chronic liver disease is recommended for hepatotoxic drugs 1, 2
No liver monitoring is needed for streptomycin and ethambutol, but baseline audiogram and vestibular testing are recommended for streptomycin, and baseline visual acuity by Snellen chart and renal function are recommended for ethambutol 1, 2, 3